Company: INDP
Filing Date: 2025-07-01
Form Type: 8-K
Source: 0001641172-25-017283
Chunk: 2

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-07-01
Form: 8-K
Item: Item 1.01
Chunk 2
---
 and 10.3 to the Prior 8-K and are incorporated by reference herein.

Paulson
Investment Company, LLC (“ Paulson”) served as the exclusive placement agent for the issuance and sale of securities of the
Company pursuant to a Placement Agent Agreement (the “ PAA”) between the Company and Paulson. As compensation for such placement
agent services, the Company has agreed to pay Paulson an aggregate cash fee equal to 12.0% of the gross proceeds received by the Company
from the offering, and a non-accountable expense of $25,000. In addition, Paulson is entitled to certain tail rights for a period of
one year following the termination or expiration of the PAA. The Placement Agent will also receive warrants (the “ Placement Agent
Warrants”) to purchase a number of shares of the Company’s Common Stock equal to 12.0% of the Conversion Shares issuable
upon conversion of the Notes sold in the offering. The Placement Agent Warrants will have the same terms as the Warrants (except that
the Placement Agent Warrants contain a cashless exercise feature) and expire on the fifth anniversary of the issue date. The PAA contains
certain customary representations and warranties and indemnification obligations of the Company and Paulson.

A
description of the PAA is qualified by reference to the full text of such document, a form of which is filed as Exhibit 10.4 to the Prior
8-K and is incorporated by reference herein.

This
Form 8-K shall not constitute an offer to sell or the solicitation of any offer to buy the securities discussed herein, nor shall there
be any offer, solicitation or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such state.